A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Participants With Multiple Myeloma That is Resistant to Current Standard of Care Treatments

Phase 1b Study of REGN5458 (Anti-BCMA x Anti-CD3 Bispecific Antibody) Plus Other Cancer Treatments for Patients With Relapsed/Refractory Multiple Myeloma

This study is researching an experimental drug called linvoseltamab in combination with other drugs for the treatment of a blood cancer called multiple myeloma. Linvoseltamab has previously been studied as a single agent (without other cancer treatments) in participants with multiple myeloma that returned after prior therapies and needed to be treated again.

In the initial study, some participants treated with linvoseltamab had improvement of their myeloma, including complete responses (no evidence of myeloma in their bodies).

This study is the first time linvoseltamab will be combined with other cancer therapies.

The main goal is to understand if linvoseltamab can be given safely with other cancer treatments, and if so, what dose of linvoseltamab should be used for each combination.

The study is looking at several other research questions, including:

• How many participants treated with linvoseltamab in combination with each of the other cancer treatments have improvement of their multiple myeloma
• What side effects may happen from taking linvoseltamab together with another cancer treatment
• How much study drug is in the blood at different times
• Whether the body makes antibodies against the study drug(s) (which could make the study drug(s) less effective or could lead to side effects)

Study Overview

• Status: Recruiting
• Conditions: Multiple Myeloma
• Intervention / Treatment: Drug: Cemiplimab; Drug: Fianlimab; Drug: Daratumumab; Drug: Lenalidomide; Drug: Linvoseltamab; Drug: Carfilzomib; Drug: Pomalidomide; Drug: Bortezomib; Drug: Isatuximab; Drug: Nirogacestat; Drug: Cevostamab

• Study Type: Interventional
• Enrollment (Estimated): 317
• Phase: Phase 1

Contacts and Locations

• Study Contact: Name: Clinical Trials Administrator; Phone Number: 844-734-6643; Email: clinicaltrials@regeneron.com

Study Locations

• France
  • Angers, France, 49933
    • Recruiting
    • Centre Hospitalier Universitaire Angers
  • Montpellier, France, 34295
    • Recruiting
    • CHU Montpellier - Departement D'Hematologie
  • Paris, France, 75571
    • Recruiting
    • Saint Antoine Hospital
  • Villejuif, France, 94805
    • Recruiting
    • Institut Gustave Roussy
  • New Aquitaine
    • Poitiers, New Aquitaine, France, 86021
      • Recruiting
      • Centre Hospitalier Universitaire (CHU) de Poitiers
  • Nord
    • Lille, Nord, France, 59037
      • Suspended
      • CHU de Lille - Rue Michel Polonovski
  • Pays de la Loire Region
    • Nantes, Pays de la Loire Region, France, 44093
      • Recruiting
      • Nantes University Hospital
  • Île-de-France Region
    • Créteil, Île-de-France Region, France, 94000
      • Recruiting
      • Hospital Henri Mondor
    • Paris, Île-de-France Region, France, 75015
      • Recruiting
      • Hopital Necker
    • Paris, Île-de-France Region, France, 75010
      • Recruiting
      • Saint Louis Hospital
• Greece
  • Athens, Greece, 11528
    • Recruiting
    • General Hospital of Athens Alexandra
  • Attica
    • Athens, Attica, Greece, 10676
      • Recruiting
      • Evangelismos General Hospital
• Israel
  • Haifa, Israel, 3109601
    • Recruiting
    • Rambam Health Care Campus
  • Jerusalem, Israel, 91120
    • Recruiting
    • Hadassah Medical Center
  • Central District
    • Ramat Gan, Central District, Israel, 5265601
      • Recruiting
      • Sheba Medical Center
• Spain
  • Barcelona, Spain, 08035
    • Recruiting
    • Hospital Universitario Vall D'Hebron
  • Barcelona, Spain, 08036
    • Recruiting
    • Hospital Clínic de Barcelona
  • Barcelona, Spain, 08908
    • Recruiting
    • Institut Catala d'Oncologia (ICO) - Hospital Duran i Reynals,
  • Madrid, Spain, 28050
    • Recruiting
    • Hospital Universitario HM Sanchinarro
  • Madrid, Spain, 28027
    • Recruiting
    • Clinica Universidad de Navarra - Madrid
  • Madrid, Spain, 28006
    • Recruiting
    • Universitaru Hospital La Princesa
  • Madrid, Spain, 28041
    • Recruiting
    • University Hospital and Research Institute
  • Madrid, Spain, 28034
    • Recruiting
    • Hospital Universitario Ramon y Cajal - Servicio de Psiquiatria
  • Salamanca, Spain, 37007
    • Recruiting
    • University Hospital of Salamanca
  • A Coruna
    • Santiago de Compostela, A Coruna, Spain, 15706
      • Recruiting
      • Hospital Clínico Universitario de Santiago
  • Barcelona
    • Badalona, Barcelona, Spain, 08916
      • Recruiting
      • Hospital Germans Trias i Pujol
  • Cantabria
    • Santander, Cantabria, Spain, 39008
      • Recruiting
      • Hospital Universitario Marqués de Valdecilla
  • Madrid
    • Pozuelo de Alarcón, Madrid, Spain, 28223
      • Recruiting
      • Hospital Universitario Quiron Salud Madrid
  • Navarre
    • Pamplona, Navarre, Spain, 31008
      • Recruiting
      • Clínica Universidad de Navarra
• United States
  • California
    • La Jolla, California, United States, 92037
      • Recruiting
      • Scripps Clinic Torrey Pines
  • Georgia
    • Atlanta, Georgia, United States, 30004
      • Recruiting
      • Winship Cancer Institute of Emory University
  • Indiana
    • Indianapolis, Indiana, United States, 46202
      • Recruiting
      • Indiana University Health Simon Cancer Center
  • Massachusetts
    • Boston, Massachusetts, United States, 02215
      • Recruiting
      • Dana Farber/Harvard Cancer Center
  • Michigan
    • Detroit, Michigan, United States, 48201
      • Recruiting
      • Karmanos Cancer Institute
  • Minnesota
    • Rochester, Minnesota, United States, 55905
      • Recruiting
      • Mayo Clinic
  • New York
    • New York, New York, United States, 10021
      • Recruiting
      • Weill Cornell Medicine/New York Presbyterian Hospital
    • New York, New York, United States, 10032
      • Recruiting
      • New York Presbyterian Hospital Columbia University Medical Center
  • North Carolina
    • Chapel Hill, North Carolina, United States, 27599
      • Recruiting
      • University of North Carolina at Chapel Hill
    • Winston-Salem, North Carolina, United States, 27157
      • Recruiting
      • Wake Forest University Health Sciences
  • Ohio
    • Columbus, Ohio, United States, 43210
      • Recruiting
      • The Ohio State University James Cancer Hospital
  • Texas
    • Dallas, Texas, United States, 75390
      • Recruiting
      • University of Texas Southwestern
  • Washington
    • Seattle, Washington, United States, 98108
      • Recruiting
      • VA Puget Sound Health Care System

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No

Description

General Key Inclusion Criteria:

1. Eastern Cooperative Oncology Group (ECOG) performance status ≤1
2. Participants must have measurable disease as defined in the protocol according to IMWG consensus criteria
3. Adequate creatinine clearance, hematologic function and hepatic function, as defined in protocol
4. Life expectancy of at least 6 months

Cohort Specific Inclusion Criteria:

For cohorts 1-6, each participant must have RRMM with progression following at least 3 lines of therapy, or at least 2 lines of therapy and either prior exposure to at least 1 anti-CD38 antibody, 1 immunomodulatory imide drug (IMiD) and 1 Proteasome Inhibitor (PI), or double-refractory to 1 PI and 1 IMiD, or the combination of 1 PI and 1 IMiD Cohort 1: Prior treatment with daratumumab is allowed if previously tolerated, as described in the protocol Cohort 2: Prior treatment with carfilzomib is allowed if previously tolerated at the approved full dose, as described in the protocol Cohort 3: Prior treatment with lenalidomide is allowed if previously tolerated at the approved full dose, as described in the protocol Cohort 4: Prior treatment with bortezomib is allowed if previously tolerated at the approved full dose, as described in the protocol Cohort 5: Prior treatment with pomalidomide is allowed if previously tolerated at the approved full dose, as described in the protocol Cohort 6: Prior treatment with isatuximab is allowed if previously tolerated, as described in the protocol

Cohort 7 and 8:

1. For participants without measurable disease by biochemical parameters [serum or urine M-protein, or serum involved Free Light Chain (FLC)], presence of at least 1 soft tissue plasmacytoma with a single diameter of ≥2 cm
2. RRMM with progressive disease and received at least 3 lines of therapy including exposure to at least 1 anti-CD38 antibody, 1 IMiD, and 1 PI or triple-class refractory disease (anti-CD38 antibody, IMiD, PI) Cohort 9: Progressive RRMM in participants with triple-class refractory disease (anti-CD38 antibody, IMiD, PI) after at least 3 lines of therapy Cohort 10: Progressive RRMM after at least 3 lines of therapy including exposure to at least 1 anti-CD38 antibody, 1 IMiD, and 1 PI

General Key Exclusion Criteria:

1. Diagnosis of plasma cell leukemia, primary light-chain amyloidosis (excluding myeloma associated amyloidosis), Waldenström macroglobulinemia (lymphoplasmacytic lymphoma), or POEMS syndrome (Polyneuropathy, Organomegaly, Endocrinopathy, Monoclonal protein, and Skin changes)
2. Participants with known MM brain lesions or meningeal involvement
3. Treatment with any systemic anti-myeloma therapy within 5 half-lives or within 21 days prior to first administration of study drug regimen, whichever is shorter
4. History of allogeneic and autologous stem cell transplantation, as described in the protocol
5. Unless stated otherwise in a specific sub-protocol, prior treatment with a T cell-based immunotherapy directed against B-Cell Maturation Antigen (BCMA) bispecific antibodies and Bispecific T-cell Engagers (BiTEs), and BCMA Chimeric Antigen Receptor (CAR) T cells (Note: BCMA antibody-drug conjugates are not excluded)
6. History of progressive multifocal leukoencephalopathy, neurodegenerative condition or Central Nervous System (CNS) movement disorder or participants with a history of seizure within 12 months prior to study enrollment are excluded
7. Live or attenuated vaccination within 28 days prior to first study drug regimen administration with a vector that has replicative potential
8. Cardiac ejection fraction <40% by Echocardiogram (Echo) or Multigated Acquisition (MUGA) scan

Cohort Specific Exclusion Criteria:

Cohort 2: Dose expansion: Prior treatment with a BCMA-directed CAR T-cell therapy will not be exclusionary if completed at least 12 weeks prior to first study treatment Cohort 3: Known malabsorption syndrome or pre-existing gastrointestinal (GI) condition that may impair absorption of lenalidomide; delivery of lenalidomide via nasogastric tube or gastrostomy tube is not allowed Cohort 4: Peripheral neuropathy grade ≥2 Cohort 5: Known malabsorption syndrome or pre-existing GI conditions that may impair absorption of pomalidomide; delivery of pomalidomide via nasogastric tube or gastrostomy tube is not allowed

Cohort 7:

1. Prior treatment with anti-Lymphocyte Activation Gene 3 (LAG-3) agents. Prior exposure to vaccine therapies or other immune checkpoint modulating therapies such as anti-Programmed cell Death Protein 1 (PD-1) antibodies is permitted, as described in the protocol
2. Ongoing or recent (within 2 years) evidence of an autoimmune disease that has required systemic treatment with immunosuppressive agents, as described in the protocol
3. Prior solid organ transplant
4. History of grade ≥3 immune-mediated adverse events (with the exclusion of endocrinopathies that are fully controlled by hormone replacement) from prior checkpoint inhibitor therapies

Cohort 8:

1. Prior treatment with anti-PD-1 or anti-PD-L1 agents. Prior exposure to vaccine therapies or other immune checkpoint modulating therapies such as anti-Cytotoxic T Lymphocyte-Associated Antigen 4 (CTLA-4) antibodies is permitted, as described in the protocol
2. Encephalitis or meningitis in the year prior to enrollment
3. History of interstitial lung disease (eg, idiopathic pulmonary fibrosis or organizing pneumonia), of active, noninfectious pneumonitis that required immune-suppressive doses of glucocorticoids to assist with management, or of pneumonitis within the last 5 years. A history of radiation pneumonitis in the radiation field is permitted as long as pneumonitis resolved ≥6 months prior to enrollment
4. Ongoing or recent (within 2 years) evidence of an autoimmune disease that has required systemic treatment with immunosuppressive agents, as described in the protocol.
5. Prior solid organ transplant
6. History of grade ≥3 immune-mediated adverse events (with the exclusion of endocrinopathies that are fully controlled by hormone replacement) from prior checkpoint inhibitor therapies

Cohort 9:

1. Abnormal QT interval corrected by Fridericia's formula (QTcF), as described in the protocol
2. Use of concomitant medications that are known to prolong the QT/QTcF interval including Class Ia and Class III antiarrhythmics at the time of informed consent
3. Ongoing use or anticipated use of food or drugs that are known strong/moderate cytochrome P450 (CYP)3A4 inhibitors, or strong CYP3A inducers within 14 days prior to first dose of nirogacestat
4. Known malabsorption syndrome or existing gastrointestinal GI condition that may impair absorption of nirogacestat; delivery of nirogacestat via nasogastric tube or gastrostomy tube is not allowed

Cohort 10:

1. Known or suspected active Epstein-Barr Virus (EBV) infection
2. Known history of Hemophagocytic Lymphohistiocytosis/Macrophage Activation Syndrome (HLH/MAS)
3. Prior treatment with cevostamab or another agent with the same target [Fragment crystallizable Receptor-like 5 (FcRH5)]

Dose finding portion: Prior treatment with any BCMA-directed immunotherapy will not be exclusionary, as described in the protocol Dose expansion portion: Prior treatment with any T cell-engaging bispecific antibody directed against BCMA will be exclusionary, as described in the protocol

NOTE: Other protocol defined inclusion/exclusion criteria apply

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Non-Randomized
• Interventional Model: Sequential Assignment
• Masking: None (Open Label)

Number of Arms

10

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Cohort 1: Linvoseltamab + Daratumumab; Linvoseltamab + Daratumumab	Drug: Daratumumab; Administered per the protocol; Other Names: Darzalex®; Darzalex Faspro™; Drug: Linvoseltamab; Administered per the protocol; Other Names: REGN5458; Lynozyfic™
Experimental: Cohort 2: Linvolseltamab + Carfilzomib; Linvoseltamab + Carfilzomib	Drug: Linvoseltamab; Administered per the protocol; Other Names: REGN5458; Lynozyfic™; Drug: Carfilzomib; Administered per the protocol; Other Names: Kyprolis®
Experimental: Cohort 3: Linvoseltamab + Lenalidomide; Linvoseltamab + Lenalidomide	Drug: Lenalidomide; Administered per the protocol; Other Names: Revlimid®; Drug: Linvoseltamab; Administered per the protocol; Other Names: REGN5458; Lynozyfic™
Experimental: Cohort 4: Linvoseltamab + Bortezomib; Linvoseltamab + Bortezomib	Drug: Linvoseltamab; Administered per the protocol; Other Names: REGN5458; Lynozyfic™; Drug: Bortezomib; Administered per the protocol; Other Names: Velcade®
Experimental: Cohort 5: Linvoseltamab + Pomalidomide; Linvoseltamab + Pomalidomide	Drug: Linvoseltamab; Administered per the protocol; Other Names: REGN5458; Lynozyfic™; Drug: Pomalidomide; Administered per the protocol; Other Names: Imnovid, Pomalyst®
Experimental: Cohort 6: Linvoseltamab + Isatuximab; Linvoseltamab + Isatuximab	Drug: Linvoseltamab; Administered per the protocol; Other Names: REGN5458; Lynozyfic™; Drug: Isatuximab; Administered per the protocol; Other Names: Sarclisa®
Experimental: Cohort 7: Linvoseltamab + Fianlimab; Linvoseltamab + Fianlimab	Drug: Fianlimab; Administered per the protocol; Other Names: REGN3767; Drug: Linvoseltamab; Administered per the protocol; Other Names: REGN5458; Lynozyfic™
Experimental: Cohort 8: Linvoseltamab + Cemiplimab; Linvoseltamab + Cemiplimab	Drug: Cemiplimab; Administered per the protocol; Other Names: REGN2810; LIBTAYO; Drug: Linvoseltamab; Administered per the protocol; Other Names: REGN5458; Lynozyfic™
Experimental: Cohort 9: Linvoseltamab + Nirogacestat; Linvoseltamab + Nirogacestat	Drug: Linvoseltamab; Administered per the protocol; Other Names: REGN5458; Lynozyfic™; Drug: Nirogacestat; Administered per the protocol; Other Names: PF-03084014
Experimental: Cohort 10: Linvoseltamab + Cevostamab; Linvoseltamab + Cevostamab	Drug: Linvoseltamab; Administered per the protocol; Other Names: REGN5458; Lynozyfic™; Drug: Cevostamab; Administered per the protocol; Other Names: RO7187797; BFCR4350A

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Incidence of Serious Adverse Events (SAEs)		Up to 5 Years
Severity of TEAEs		Up to 5 Years
Severity of SAEs		Up to 5 Years
Severity of AESIs		Up to 5 Years
Incidence of laboratory abnormalities	≥ grade 3 per National Cancer Institute-Common Terminology Criteria for Adverse Events [NCI-CTCAE v5.0]	Up to 5 Years
Incidence of Dose Limiting Toxicities (DLTs) for each study regimen during the observation period	Dose finding portion only	Up to 28 Days
Incidence of Treatment-Emergent Adverse Events (TEAEs)		Up to 5 Years
Incidence of Adverse Events of Special Interest (AESIs)		Up to 5 Years

Secondary Outcome Measures

Outcome Measure	Time Frame
Overall Survival (OS)	Up to 5 Years
Concentrations of total linvoseltamab in serum over time	Up to 5 Years
Overall Response Rate (ORR) as measured by International Myeloma Working Group (IMWG) criteria	Up to 5 Years
Duration of Response (DOR) by IMWG criteria	Up to 5 Years
Progression-Free Survival (PFS) as measured by IMWG criteria	Up to 5 Years
Rate of Minimal Residual Disease (MRD) negative status by IMWG criteria	Up to 5 Years
Incidence over time of Anti-Drug Antibodies (ADAs) to linvoseltamab	Up to 5 Years

Collaborators and Investigators

• Sponsor: Regeneron Pharmaceuticals
• Investigators: Study Director: Clinical Trial Management, Regeneron Pharmaceuticals

Study record dates

Study Major Dates

• Study Start (Actual): August 17, 2022
• Primary Completion (Estimated): March 25, 2028
• Study Completion (Estimated): March 24, 2032

Study Registration Dates

• First Submitted: November 18, 2021
• First Submitted That Met QC Criteria: November 18, 2021
• First Posted (Actual): November 30, 2021

Study Record Updates

• Last Update Posted (Actual): July 8, 2026
• Last Update Submitted That Met QC Criteria: July 6, 2026
• Last Verified: June 1, 2026

More Information

Terms related to this study

• Keywords: B-cell maturation antigen (BCMA); Relapsed/Refractory Multiple Myeloma (RRMM); Anti-CD3 monoclonal antibodies (mAbs)
• Additional Relevant MeSH Terms: Vascular Diseases; Cardiovascular Diseases; Neoplasms; Immune System Diseases; Neoplasms by Histologic Type; Hematologic Diseases; Lymphoproliferative Disorders; Immunoproliferative Disorders; Neoplasms, Plasma Cell; Hemostatic Disorders; Paraproteinemias; Blood Protein Disorders; Hemorrhagic Disorders; Hemic and Lymphatic Diseases; Multiple Myeloma; Organic Chemicals; Heterocyclic Compounds, 1-Ring; Heterocyclic Compounds; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Carboxylic Acids; Piperidines; Inorganic Chemicals; Boronic Acids; Acids, Noncarboxylic; Acids; Boron Compounds; Pyrazines; Phthalimides; Phthalic Acids; Acids, Carbocyclic; Piperidones; Isoindoles; Lenalidomide; Bortezomib; carfilzomib; pomalidomide; daratumumab; cemiplimab; isatuximab; nirogacestat
• Other Study ID Numbers: R5458-ONC-2012; 2020-004638-39 (EudraCT Number); 2023-506247-42-00 (Ctis: EU CT Number)

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: YES
• IPD Plan Description: All Individual Patient Data (IPD) that underlie publicly available results will be considered for sharing

IPD Sharing Time Frame

When Regeneron has:

• received marketing authorization from major health authorities (e.g., FDA, European Medicines Agency (EMA), Pharmaceuticals and Medical Devices Agency (PMDA), etc.) for the product and indication or has globally discontinued development of the product for all indications on or after April 2020 and has no plans for future development
• made the study results publicly available (e.g., scientific publication, scientific conference, clinical trial registry)
• the legal authority to share the data, and
• ensured the ability to protect participant privacy

• IPD Sharing Access Criteria: Qualified researchers can submit a proposal for access to individual patient or aggregate level data from a Regeneron-sponsored clinical trial through Vivli. Regeneron's Independent Research Request Evaluation Criteria can be found at: https://www.regeneron.com/sites/default/files/Regeneron-External-Data-Sharing-Policy-and-Independent-Research-Request-Evaluation-Criteria.pdf
• IPD Sharing Supporting Information Type: STUDY_PROTOCOL; SAP; ICF; ANALYTIC_CODE; CSR

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: Yes
• Studies a U.S. FDA-regulated device product: No